Market Overview

FBR Capital Initiates TherapeuticsMD At Outperform, Shares Jump

TherapeuticsMD Reports Closing of Enrollment in REJOICE Trial for TX-004HR
Events for the Week of Nov. 17-21, 2014

FBR Capital Markets initiated coverage on shares of TherapeuticsMD (NYSE: TXMD) with an “outperform” rating.

The target price for TherapeuticsMD is set to $34.

TherapeuticsMD shares have jumped 54.10% over the past 52 weeks, while the S&P 500 index has gained 19.69% in the same period.

TherapeuticsMD's shares jumped 32.93% to $5.49 in pre-market trading.

Latest Ratings for TXMD

Jun 2015Guggenheim SecuritiesInitiates Coverage onBuy
Jul 2014FBR CapitalInitiates Coverage onOutperform
Jun 2014JMP SecuritiesInitiates Coverage onMarket Outperform

View More Analyst Ratings for TXMD
View the Latest Analyst Ratings

Posted-In: FBR Capital MarketsInitiation Analyst Ratings


Related Articles (TXMD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters